[{"id":"b25768d2-e63d-4ef1-89e9-0d4fc5455a84","acronym":"","url":"https://clinicaltrials.gov/study/NCT05489237","created_at":"2022-08-05T13:57:06.723Z","updated_at":"2024-07-02T16:35:10.688Z","phase":"Phase 1","brief_title":"A First-in-human (FIH) Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) [Study ID: StrateGIST 1]","source_id_and_acronym":"NCT05489237","lead_sponsor":"IDRx, Inc.","biomarkers":" PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • PDGFRA exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • IDRX-42"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 04/24/2026","primary_completion_date":" 04/24/2026","study_txt":" Completion: 09/13/2026","study_completion_date":" 09/13/2026","last_update_posted":"2024-04-09"},{"id":"28db9516-1c03-4c8b-98d1-37ee5af86d30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03862885","created_at":"2021-01-18T19:03:16.863Z","updated_at":"2024-07-02T16:36:42.722Z","phase":"","brief_title":"Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST","source_id_and_acronym":"NCT03862885","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation • PDGFRA exon 18 mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation • PDGFRA exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-27"},{"id":"05655b81-f61f-4430-a051-3fbad631a8f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02776878","created_at":"2021-01-18T13:37:00.696Z","updated_at":"2024-07-02T16:37:32.017Z","phase":"","brief_title":"A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GIST","source_id_and_acronym":"NCT02776878","lead_sponsor":"Peking University Cancer Hospital \u0026 Institute","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT exon 11 mutation • PDGFRA mutation • KIT wild-type • PDGFRA exon 18 mutation • PDGFR wild-type","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 11 mutation • PDGFRA mutation • KIT wild-type • PDGFRA exon 18 mutation • PDGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dasatinib"],"overall_status":"Unknown status","enrollment":" Enrollment 57","initiation":"Initiation: 05/01/2016","start_date":" 05/01/2016","primary_txt":" Primary completion: 10/01/2017","primary_completion_date":" 10/01/2017","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2016-05-18"}]